An fMRI Study of Treatment Optimization Recommendations Comparing Patients Continuing Treatment with Glatiramer Acetate 20mg qd SC (Copaxone) to Those Randomized to IFN-ß-1a 44mcg tiw SC (Rebif) in a Multicenter Study of Patients with Relapsing Remitting

Project: Research project

Project Details

StatusFinished
Effective start/end date6/15/06 → 6/15/09

Funding

  • Neurognostics, Inc (Agmt 6/15/06)